Clinical trial

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

NCT06769425

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-05-07

PhasePHASE1

Study timeline

Study start (actual)2025-05-07Date precision: day

Registry last updated2025-06-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Recurrent Ovarian Cancerunresolved

HER2-negativeunresolved

Advanced Breast Cancerunresolved

TNBCunresolved

Advanced Prostate Cancerunresolved

Advanced Gastric Cancerunresolved

Interventions

HS-10502 + NHADRUG

HS-10502 + HS-20093DRUG

HS-10502+ ApatinibDRUG

HS-10502 + HS-20089DRUG

HS-10502 + Platinum + BevacizumabDRUG

HS-10502 + nab-paclitaxel or Docetaxel or IrinotecanDRUG

HS-10502 + BevacizumabDRUG

Sponsors & collaborators

Jiangsu Hansoh Pharmaceutical Co., Ltd.lead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06769425 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.